非小细胞肺癌预后相关评价标志物的筛选  

Screening of prognostic biomarkers for non-small cell lung cancer

作　　者：李俊甫[1] 申伟科[1] 祖金池[2] 仉洁[1] 张旭朏[1] 张磊[1] 钟理[1] 

机构地区：[1]河北大学生命科学学院,河北保定071002 [2]河北大学附属医院胸外科,河北保定071000

出　　处：《中华实用诊断与治疗杂志》2014年第6期537-539,共3页Journal of Chinese Practical Diagnosis and Therapy

基　　金：国家自然科学基金(81272444;81071795)

摘　　要：目的利用生物芯片技术和非小细胞肺癌(non-small cell lung cancer,NSCLC)患者血清及随访结果,筛选出新型NSCLC高敏感性和特异性的血清自身免疫抗体作为分子标志物用于NSCLC的预后评价。方法 (1)提取NSCLC组织总mRNA构建T7噬菌体cDNA文库;(2)用NSCLC预后良好和不良患者血清对T7文库进行生物淘洗;(3)构建蛋白芯片,分别用预后良好和不良患者血清孵育芯片进行Cy5/Cy3双荧光标记并分析芯片结果;(4)对挑选出的标志物进行测序及分析。结果筛选得到最佳评价组合含6个NSCLC预后相关标志物,其联合诊断准确率80.7%,敏感性85.3%,特异性73.9%,AUC为0.825;测序及BLAST分析显示,abl-interactor 1、pleiotrophin、surfactant protein B 3个标志物是已知癌细胞转移和预后相关分子。结论成功筛选得到1个含有6个标志物的最佳评价组合,可对NSCLC预后进行较准确诊断。Objective To identify the prognosis-associated autoantibody biomarkers with high sensitivity and specificity from the serum samples in non-small cell lung cancer （NSCLC） patient by using phage-display and protein microarray techniques. Methods mRNA was extracted from NSCLC tissue to construct T7 cDNA library. The library was biopanned with two types of sera from patients with poor or good prognosis. Protein microarray chips were tested by the serum samples from the patients with good or poor prognosis respectively. CyS/Cy3 signal for each phage clone was extracted from the chips. The biomarkers used for the classifier development were sequenced and the identities were analyzed. Results After training and validation test, a classifier was developed using a combination of six NSCLC prognosis biomarkers. The combined diagnosis accuracy rate reached 80.7%, the sensitivity was 85.3%, the specificity was 73.9%, and the AUC was 0. 825. Sequencing and BLAST results indicated that 3 of the 6 biomarkers had cancer metastasis and prognosis properties, as abl-interactor 1, pleiotrophin and surfactant protein B. Conclusions A panel of 6 autoantibody biomarkers have been identified successfully, which can accurately predict the prognosis of NSCLC.

关 键 词：非小细胞肺癌 预后 蛋白芯片 自身免疫抗体 

分 类 号：R734.2[医药卫生—肿瘤]